J Korean Surg Soc.  2009 Aug;77(2):75-81. 10.4174/jkss.2009.77.2.75.

The Timing of Recurrence Dependent on Menopausal Status after Surgery for Breast Cancer

• Lee JJ
• Jung JH
• Park HY

• KMID: 2211285
• DOI: http://doi.org/10.4174/jkss.2009.77.2.75

Abstract

PURPOSE
This study was aimed at evaluating the timing of clinical recurrence after surgical removal of the primary tumor. METHODS: The hazard rate for recurrence during the first 5 years after surgery was studied in 1,225 female patients from 1995 to 2003 at Kyungpook National University Hospital. Subset analyses were performed according to menopausal status and axillary lymph node involvement. RESULTS: The group of premenopausal women has one peak hazard rate in the 18~24 month period after surgery, while that of postmenopausal women has two peaks at 18~24 months and 42~48 months. The hazard rate of node positive group is much higher than node negative group at all periods. In the premenopausal group, patients with less than 3 node metastases have a peak hazard rate at about 18~24 months, while those with more than 4 lymph node metastases have that in 6~12 months. In the postmenopausal group, patients with less than 3 node metastases have the peak hazard rate at 18~24 months, while more than 4 lymph node metastases have two peaks at 18~24 months and 42~48 months. CONCLUSION: Both premenopausal and postmenopausal groups similarly show the peaked hazard rate of recurrence at about 2 years after surgery. In premonopausal young women, the status of nodal metastasis affects early recurrence, while in postmenopausal women, more nodal metastasis related with late recurrence at about 45 months. Menopausal status according to axillary node involvement shows the different recurrence pattern.

Keyword

Breast cancer; Menopausal status; Axillary node; Recurrent rate

MeSH Terms

Breast
Breast Neoplasms
Female
Humans
Lymph Nodes
Neoplasm Metastasis
Recurrence

Figure

• 

  Fig. 1 Hazard rate for breast cancer recurrence (local-regional plus distant) after mastectomy (MRM*/partial mastectomy+RTx†) as primary treatment in 1,225 patients (5 years follow-up). *MRM = modified radical mastectomy; †RTx = radiation therapy.

• 

  Fig. 2 Hazard rate for breast cancer recurrence (local-regional plus distant). (A) Pre-menopausal patients, (B) Post-menopausal patients.

• 

  Fig. 3 Hazard rate for breast cancer recurrence (local-regional plus distant). (A) Node-negative, (B) Node-positive.

• 

  Fig. 4 Hazard rate for breast cancer recurrence (local-regional plus distant) in pre-menopausal patients. (A) N0-N1, (B) N2-N3.

• 

  Fig. 5 Hazard rate for breast cancer recurrence (local-regional plus distant) in post-menopausal patients. (A) N0-N1, (B) N2-N3.

Reference

1. Ko SS. Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996~2006) using nationwide breast cancer registration on-line program: biannual update. J Surg Oncol. 2008. 98:318–323.

2. Im TH, Jung PJ. The patterns, the survival, and the change of serologic markers after recurrence in patients with breast cancer. J Korean Surg Soc. 1998. 54:313–322.

3. Park KH, Kim SI, Ko SS, Park BW, Lee KS. The pattern of systemic failure and factors influencing on the outcome after distant metastastasis in breast cancer. J Korean Breast Cancer Soc. 2003. 6:109–116.

4. Bland KI, Copeland EM III. Schwartz SI, Shires GT, Spencer FC, editors. Breast. Principles of Surgery. 1994. 6th ed. New York: McGraw-Hill;554–557.

5. Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005. 89:173–178.

6. Baum M, Badwe RA. Wise L, Johnson H, editors. Does surgery influence the natural history of breast cancer. Breast Cancer: Controversies in Management. 1994. Armonk, NY: Futura Publishing Company;61–69.

7. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996. 41:177–185.

8. Ernst MF, Voogd AC, Coebergh JW, Poortmans PM, Roukema JA. Using loco-regional recurrence as an indicator of the quality of breast cancer treatment. Eur J Cancer. 2004. 40:487–493.

9. Son BH, Lee PC, Yoon HS, Kwak HS, Lee KC, Kim CS, et al. Patterns of locoregional and systemic failure after a mastectomy in breast cancer and risk factors predicting failure. J Korean Surg Soc. 2000. 59:305–312.

10. Blanco G, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P. Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. Br J Cancer. 1990. 62:142–146.

11. Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer. 1978. 41:1170–1178.

12. Horst KC, Smitt MC, Goffinet DR, Carlson RW. Predictors of local recurrence after breast-conservation therapy. Clin Breast Cancer. 2005. 5:425–438.

13. Huston TL, Simmons RM. Locally recurrent breast cancer after conservation therapy. Am J Surg. 2005. 189:229–235.

14. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001. 19:1688–1697.

15. Arriagada R, Le MG, Contesso G, Guinebretiere JM, Rochard F, Spielmann M. Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol. 2002. 13:1404–1413.

16. Gasparini G, Biganzoli E, Bonoldi E, Morabito A, Fanelli M, Boracchi P. Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2001. 65:71–75.

17. Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999. 91:80–85.

18. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996. 14:2738–2746.

19. Demicheli R, Bonadonna G, Hrushesky WJ, Retsky MW, Valagussa P. Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Res. 2004. 6:R689–R696.

20. Bijker N, Rutgers EJ, Peterse JL, van Dongen JA, Hart AA, Borger JH, et al. Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy. Cancer. 1999. 85:1773–1781.

21. Kim JS, Noh DY, Yoon Y, Oh SK, Choe KJ. Analysis of postoperative survival and prognostic factors in breast cancer. J Korean Surg Soc. 1998. 54:640–648.

22. Shim KS, Park CS, Min JS, Lee KS. A study on prognostic factors influencing treatment results in breast cancer patients. J Korean Surg Soc. 1991. 40:716–723.

23. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975. 36:1–85.

24. Kim SW, Kim HJ, Chung KW, Noh DY, Youn YK, Oh SK, et al. The investigation of an age as a prognostic factor of breast cancer. J Korean Surg Soc. 2003. 64:20–27.

25. Yildirim E, Dalgic T, Berberoglu U. Prognostic significance of young age in breast cancer. J Surg Oncol. 2000. 74:267–272.

26. Retsky M, Demicheli R, Hrushesky W. Premenopausal status accelerates relapse in node positive breast cancer: hypothesis links angiogenesis, screening controversy. Breast Cancer Res Treat. 2001. 65:217–224.

27. Heer K, Kumar H, Speirs V, Greenman J, Drew PJ, Fox JN, et al. Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery? Br J Cancer. 1998. 78:1203–1207.

28. Hrushesky WJ, Bluming AZ, Gruber SA, Sothern RB. Menstrual influence on surgical cure of breast cancer. Lancet. 1989. 2:949–952.

29. Hagen AA, Hrushesky WJ. Menstrual timing of breast cancer surgery. Am J Surg. 1998. 175:245–261.